GlassScriptPhysician profile
Kyle P Fluharty
NPI 1174127617
$672.12
in general payments reported to CMS, 2019-2025
12 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.72 · 2021: $148 · 2023: $151 · 2024: $98.09 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $161.60 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $152.27 | 2021-2024 | Cequa |
| Glaukos Corporation | $131.40 | 2023-2025 | Idosetr |
| Amgen INC. | $41.95 | 2025 | Tepezza |
| Alcon Vision LLC | $33.14 | 2024 | Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $32.42 | 2021 | |
| Abbvie INC. | $24.68 | 2024 | |
| Oyster Point Pharma, INC. | $22.00 | 2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $20.37 | 2021 | |
| Bausch & Lomb Americas INC. | $18.74 | 2025 | Miebo |
| Thea Pharma INC. | $16.83 | 2025 | Iyuzeh |
| Genentech USA, INC. | $16.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Fluharty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.